The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
GDF15 promotes EMT and metastasis in colorectal cancer
Open accessAbstract
// Chen Li 1, 4, * , Jingyu Wang 1, 2, 5, * , Jianlu Kong 1, 4 , Jinlong Tang 1, 3 , Yihua Wu 1 , Enping Xu 1, 4 , Honghe Zhang 1, 4 , Maode Lai 1, 4 1 Department of Pathology, School of Medicine, Zhejiang University, Zhejiang, PR China 2 Department of Pathology, the First Hospital of Jiaxing, Zhejiang, PR China 3 Department of Pathology, the Second Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang, PR China 4 Key Laboratory of Disease Proteomics of Zhejiang Province, Zhejiang, PR China 5 Key Constructing Discipline by Zhejiang Province and Jiaxing City, Zhejiang, PR China * These authors have contributed equally to this work Correspondence to: Honghe Zhang, e-mail: honghezhang@zju.edu.cn Maode Lai, e-mail: lmp@zju.edu.cn Keywords: GDF15, EMT, metastasis, colorectal cancer Received: July 21, 2015 Accepted: October 15, 2015 Published: October 22, 2015 ABSTRACT Metastasis is the major cause of cancer deaths, and the epithelial–mesenchymal transition (EMT) has been considered to be a fundamental event in cancer metastasis. However, the role of growth differentiation factor 15 (GDF15) in colorectal cancer (CRC) metastasis and EMT remains poorly understood. Here, we showed that GDF15 promoted CRC cell metastasis both in vitro and in vivo . In addition, the EMT process was enhanced by GDF15 through binding to TGF-β receptor to activate Smad2 and Smad3 pathways. Clinical data showed GDF15 level in tumor tissues, and the serum was significantly increased, in which high GDF15 level correlated with a reduced overall survival in CRC. Thus, GDF15 may promote colorectal cancer metastasis through activating EMT. Promisingly, GDF15 could be considered as a novel prognostic marker for CRC in the clinic.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Li, P.-X., Wong, J., Ayed, A., Ngo, D., Brade, A. M., Arrowsmith, C., Austin, R. C., & Klamut, H. J. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m909580199 · Cited by 254
Local and Systemic Protumorigenic Effects of Cancer-Associated Fibroblast-Derived GDF15
Bruzzese, F., Hägglöf, C., Leone, A., Sjöberg, E., Roca, M. S., Kiflemariam, S., Sjöblom, T., Hammarsten, P., Egevad, L., Bergh, A., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2259 · Cited by 127
Cited by
Growth/Differentiation Factor-15 (GDF-15): From Biomarker to Novel Targetable Immune Checkpoint
Wischhusen, J., Melero, I., & Fridman, W. H. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00951 · Cited by 506
“, colorectal (78, 79), ovarian (80), and early-stage lung cancer (79, 81).”
BackgroundRegulation of EMT in Colorectal Cancer: A Culprit in Metastasis
Vu, T., & Datta, P. (2017) · Cancers · doi:10.3390/cancers9120171 · Cited by 496
Baek, S. J., & Eling, T. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.02.008 · Cited by 194
Guo, Y., Ayers, J. L., Carter, K. T., Wang, T., Maden, S. K., Edmond, D., Newcomb P, P., Li, C., Ulrich, C., Yu, M., et al. (2019) · Aging Cell · doi:10.1111/acel.13013 · Cited by 139
Self-citationPrevalent mesenchymal drift in aging and disease is reversed by partial reprogramming
Lu, J. Y., Tu, W. B., Li, R., Weng, M., Sanketi, B. D., Yuan, B., Reddy, P., Rodriguez Esteban, C., & Izpisua Belmonte, J. C. (2025) · Cell · doi:10.1016/j.cell.2025.07.031 · Cited by 68
Metadata
- Authors
- Li, C., Wang, J., Kong, J., Tang, J., Wu, Y., Xu, E., Zhang, H., & Lai, M.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2015-10-22
- Volume
- 7
- Issue
- 1
- Pages
- 860-872
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W2255388447
- Cited by
- 170
- References
- 2
- FWCI
- 7.29
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.